Sandbox GGC4

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 12: Line 12:
Apolipoprotein A-1 is found to be as an indicator for cardiovascular disease and atherosclerotic cardiovascular disease. Since APOA1 is a component of HDL associated with good form of cholesterol, when ABOAB (apolipoprotein B) a component of LDL, a form of bad cholesterol levels are elevated in blood can signal as a risk factor for development in hardening of arterial walls and blockage. <ref> Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum</ref> High-density lipoprotein complex is important in the clearing of fats through absorption of cholesterol that is transported into the liver where it is synthesized into bile salts or excreted.<ref> LDL &amp; HDL: Good &amp; Bad Cholesterol. (2020, January 31). Retrieved November 14, 2020, from https://www.cdc.gov/cholesterol/ldl_hdl.htm</ref><ref>Cohen, D. (2008, April). Balancing cholesterol synthesis and absorption in the gastrointestinal tract. Retrieved November 14, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2390860/</ref>
Apolipoprotein A-1 is found to be as an indicator for cardiovascular disease and atherosclerotic cardiovascular disease. Since APOA1 is a component of HDL associated with good form of cholesterol, when ABOAB (apolipoprotein B) a component of LDL, a form of bad cholesterol levels are elevated in blood can signal as a risk factor for development in hardening of arterial walls and blockage. <ref> Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum</ref> High-density lipoprotein complex is important in the clearing of fats through absorption of cholesterol that is transported into the liver where it is synthesized into bile salts or excreted.<ref> LDL &amp; HDL: Good &amp; Bad Cholesterol. (2020, January 31). Retrieved November 14, 2020, from https://www.cdc.gov/cholesterol/ldl_hdl.htm</ref><ref>Cohen, D. (2008, April). Balancing cholesterol synthesis and absorption in the gastrointestinal tract. Retrieved November 14, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2390860/</ref>
-
Apolipoprotein A-I(Milano) is a mutant form of apolipoprotein A-I associated in reducing coronary artery disease to those genetically predisposition. <ref>CR;, C. (n.d.). Apolipoprotein A-I(Milano): Current perspectives. Retrieved November 14, 2020, from https://pubmed.ncbi.nlm.nih.gov/12642784/</ref> Mutation Milano was first discovered in from a patient in Limone sul Garda, Northern Italy or alarming elevated triglycerides and low HDL with no signs of atherosclerosis or cardiovascular disease. Mutation occurs at 173 residue of arginine replaced with cysteine. <ref>Lowe, D. (2016, November 16). The Long Saga of Apo-A1 Milano. Retrieved November 14, 2020, from https://blogs.sciencemag.org/pipeline/archives/2016/11/16/the-long-saga-of-apo-a1-milano</ref>
+
'''Apolipoprotein A-I(Milano)''' is a mutant form of apolipoprotein A-I associated in reducing coronary artery disease to those genetically predisposition. <ref>CR;, C. (n.d.). Apolipoprotein A-I(Milano): Current perspectives. Retrieved November 14, 2020, from https://pubmed.ncbi.nlm.nih.gov/12642784/</ref> Mutation Milano was first discovered in from a patient in Limone sul Garda, Northern Italy or alarming elevated triglycerides and low HDL with no signs of atherosclerosis or cardiovascular disease. Mutation occurs at 173 residue of <scene name='75/752268/Milano/1'>arginine</scene> replaced with cysteine. <ref>Lowe, D. (2016, November 16). The Long Saga of Apo-A1 Milano. Retrieved November 14, 2020, from https://blogs.sciencemag.org/pipeline/archives/2016/11/16/the-long-saga-of-apo-a1-milano</ref>
== Diseases ==
== Diseases ==

Revision as of 20:34, 14 November 2020

Apolipoprotein A-I

Structure

Apolipoprotein A-I

Drag the structure with the mouse to rotate

References

1. Voet, D., Voet, J. G., & Pratt, C. W. (2016). Fundamentals of Biochemistry (5th ed.). Hoboken, NJ: John Wiley & Sons.
  1. Voet, D., Voet, J. G., & Pratt, C. W. (2016). Fundamentals of Biochemistry (5th ed.). Hoboken, NJ: John Wiley & Sons.
  2. APOA1 gene: MedlinePlus Genetics. (2020, August 18). Retrieved October 26, 2020, from https://medlineplus.gov/genetics/gene/apoa1/
  3. Yano, K., Ohkawa, R., Sato, M., Yoshimoto, A., Ichimura, N., Kameda, T., . . . Tozuka, M. (2016, November 09). Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells. Retrieved November 14, 2020, from https://www.hindawi.com/journals/jl/2016/9891316/
  4. Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum
  5. LDL & HDL: Good & Bad Cholesterol. (2020, January 31). Retrieved November 14, 2020, from https://www.cdc.gov/cholesterol/ldl_hdl.htm
  6. Cohen, D. (2008, April). Balancing cholesterol synthesis and absorption in the gastrointestinal tract. Retrieved November 14, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2390860/
  7. CR;, C. (n.d.). Apolipoprotein A-I(Milano): Current perspectives. Retrieved November 14, 2020, from https://pubmed.ncbi.nlm.nih.gov/12642784/
  8. Lowe, D. (2016, November 16). The Long Saga of Apo-A1 Milano. Retrieved November 14, 2020, from https://blogs.sciencemag.org/pipeline/archives/2016/11/16/the-long-saga-of-apo-a1-milano

2. APOA1 gene: MedlinePlus Genetics. (2020, August 18). Retrieved October 26, 2020, from https://medlineplus.gov/genetics/gene/apoa1/

3. Mangaraj, M., Nanda, R., & Panda, S. (2016, July). Apolipoprotein A-I: A Molecule of Diverse Function. Retrieved November 04, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910842

4. Yano, K., Ohkawa, R., Sato, M., Yoshimoto, A., Ichimura, N., Kameda, T., . . . Tozuka, M. (2016, November 09). Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells. Retrieved November 14, 2020, from https://www.hindawi.com/journals/jl/2016/9891316/

5. Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum. (n.d.). Retrieved November 14, 2020, from Test ID: APOAB Apolipoprotein A1 and B, Serum

6. LDL & HDL: Good & Bad Cholesterol. (2020, January 31). Retrieved November 14, 2020, from https://www.cdc.gov/cholesterol/ldl_hdl.htm

7. Cohen, D. (2008, April). Balancing cholesterol synthesis and absorption in the gastrointestinal tract. Retrieved November 14, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2390860/

8. CR;, C. (n.d.). Apolipoprotein A-I(Milano): Current perspectives. Retrieved November 14, 2020, from https://pubmed.ncbi.nlm.nih.gov/12642784/

9. Lowe, D. (2016, November 16). The Long Saga of Apo-A1 Milano. Retrieved November 14, 2020, from https://blogs.sciencemag.org/pipeline/archives/2016/11/16/the-long-saga-of-apo-a1-milano

Personal tools